一个多类极端梯度增强模型用于评估阿尔茨海默病预测中的转录基因生物标志物
Yi Zhang1, Shasha Shen1, Xiaokai Li1
1Institute of Neuroscience, Panzhihua University, Panzhihua 617000, China.
Neuroscience letters
|December 29, 2023
概括
这项研究确定了血液转录生物标志物,以准确预测阿尔茨海默病 (AD) 的患者,即使是那些早期发病的患者. 这些发现为早期诊断和AD的管理提供了有希望的新工具.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 年轻发病的阿尔茨海默氏症 (AD) 往往表现出微妙的症状,缺乏明确的诊断标记,导致误诊.
- 免疫系统功能障碍越来越多地与神经退行性疾病的进展有关.
研究的目的:
- 为了识别血液转录基因特征,准确预测阿尔茨海默病 (AD).
- 评估这些特征在区分AD与认知正常 (CN) 和轻度认知障碍 (MCI) 的表现.
主要方法:
- 从大规模的转录组学数据中提取血液生物标志物.
- 构建和评估多类极端梯度提升 (XGBoost) 模型.
- 使用外部数据集进行独立测试以验证模型性能.
主要成果:
- 综合血液转录组签名在分类AD与CN (AUC=0.83) 和AD与MCI (AUC=0.85) 中取得了高准确性.
- 确定了与AD预测相关的显著染色体区域和转录因子.
- 生物分析表明,在神经退行性疾病中,免疫反应失调,造血,细胞外置和神经元支持的改变.
结论:
- 血液转录生物标志物显示出对AD的准确评估和预测具有重大潜力.
- 这些生物标志物可能有助于早期诊断和阿尔茨海默病的临床管理.
相关概念视频
01:26Alzheimer's Disease: Overview
491
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
491
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195